Literature DB >> 22253258

The genotype-phenotype correlation in Pompe disease.

Marian Kroos1, Marianne Hoogeveen-Westerveld, Ans van der Ploeg, Arnold J J Reuser.   

Abstract

Pompe disease is an autosomal recessive lysosomal glycogen storage disorder that is caused by acid α-glucosidase (GAA) deficiency and is due to pathogenic sequence variations in the corresponding GAA gene. The correlation between genotypes and phenotypes is strict, in that patients with the most severe phenotype, classic infantile Pompe disease, have two pathogenic mutations, one in each GAA allele, that prevent the formation of GAA or totally obliterates its function. All patients with less progressive phenotypes have at least one sequence variation that allows normal or low level synthesis of GAA leading to the formation of analytically measurable, low level GAA activity in most cases. There is an overall trend of finding higher GAA enzyme levels in patients with onset of symptoms in adulthood when compared to patients who show clinical manifestations in early childhood, aged 0-5 years, with a rapidly progressive course, but who lack the severe characteristics of classic infantile Pompe disease. However, several cases have been reported of adult-onset disease with very low GAA activity, which in all those cases corresponds with the GAA genotype. The clinical diversity observed within a large group of patients with functionally the same GAA genotype and the same c.-32-13C > T haplotype demonstrates that modifying factors can have a substantial effect on the clinical course of Pompe disease, disturbing the GAA genotype-phenotype correlation. The present day challenge is to identify these factors and explore them as therapeutic targets.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22253258     DOI: 10.1002/ajmg.c.31318

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  52 in total

1.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 2.  Glycogen metabolism and glycogen storage disorders.

Authors:  Shibani Kanungo; Kimberly Wells; Taylor Tribett; Areeg El-Gharbawy
Journal:  Ann Transl Med       Date:  2018-12

Review 3.  Molecular genetics of Pompe disease: a comprehensive overview.

Authors:  Paolo Peruzzo; Eleonora Pavan; Andrea Dardis
Journal:  Ann Transl Med       Date:  2019-07

4.  Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

Authors:  Jeong-A Lim; Baodong Sun; Rosa Puertollano; Nina Raben
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

Review 5.  Pompe Disease: From Basic Science to Therapy.

Authors:  Lara Kohler; Rosa Puertollano; Nina Raben
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

6.  The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris.

Authors:  José A Martina; Heba I Diab; Li Lishu; Lim Jeong-A; Simona Patange; Nina Raben; Rosa Puertollano
Journal:  Sci Signal       Date:  2014-01-21       Impact factor: 8.192

7.  Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease.

Authors:  Mari Mori; Gloria Haskell; Zoheb Kazi; Xiaolin Zhu; Stephanie M DeArmey; Jennifer L Goldstein; Deeksha Bali; Catherine Rehder; Elizabeth T Cirulli; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-17       Impact factor: 4.797

8.  Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.

Authors:  Thomas Hundsberger; Kai M Rösler; Oliver Findling
Journal:  J Neurol       Date:  2014-06-13       Impact factor: 4.849

9.  WITHDRAWN: Clearance of lysosomal glycogen accumulation by Transcription factor EB (TFEB) in muscle cells from lysosomal alpha-glucosidase deficient mice.

Authors:  Hoi Ming Li; Erin Feeney; Lishu Li; Hossein Zare; Rosa Puertollano; Nina Raben
Journal:  Biochem Biophys Res Commun       Date:  2013-02-14       Impact factor: 3.575

10.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.